JP2007509106A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509106A5
JP2007509106A5 JP2006536068A JP2006536068A JP2007509106A5 JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5 JP 2006536068 A JP2006536068 A JP 2006536068A JP 2006536068 A JP2006536068 A JP 2006536068A JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyridinyl
pyrimidinyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509106A (ja
JP4827737B2 (ja
Filing date
Publication date
Priority claimed from GBGB0325031.3A external-priority patent/GB0325031D0/en
Application filed filed Critical
Publication of JP2007509106A publication Critical patent/JP2007509106A/ja
Publication of JP2007509106A5 publication Critical patent/JP2007509106A5/ja
Application granted granted Critical
Publication of JP4827737B2 publication Critical patent/JP4827737B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536068A 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用 Expired - Fee Related JP4827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0325031.3 2003-10-27
GBGB0325031.3A GB0325031D0 (en) 2003-10-27 2003-10-27 Organic compounds
PCT/EP2004/012080 WO2005039586A1 (en) 2003-10-27 2004-10-26 Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders

Publications (3)

Publication Number Publication Date
JP2007509106A JP2007509106A (ja) 2007-04-12
JP2007509106A5 true JP2007509106A5 (enExample) 2007-12-13
JP4827737B2 JP4827737B2 (ja) 2011-11-30

Family

ID=29725439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536068A Expired - Fee Related JP4827737B2 (ja) 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用

Country Status (4)

Country Link
US (1) US7687512B2 (enExample)
JP (1) JP4827737B2 (enExample)
GB (1) GB0325031D0 (enExample)
WO (1) WO2005039586A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007008290A (es) 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
RU2415672C2 (ru) 2005-05-02 2011-04-10 Новартис Аг Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
WO2007065898A1 (en) * 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
JP5559043B2 (ja) * 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
JP5710251B2 (ja) * 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規ヘテロ環化合物およびその使用
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
NZ590839A (en) * 2008-08-13 2013-02-22 Novartis Ag Treatment of pulmonary arterial hypertension
US20110243957A1 (en) * 2008-09-24 2011-10-06 University Of South Florida Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
US8227477B2 (en) 2008-11-05 2012-07-24 Greta Sterimbaum Nilotinib HCl crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
WO2010096395A1 (en) * 2009-02-18 2010-08-26 Syntech Solution Llc Amides as kinase inhibitors
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
CN102917700A (zh) * 2010-03-26 2013-02-06 国立大学法人北海道大学 神经退行性疾病治疗药物
AU2012288900B2 (en) 2011-07-27 2016-10-06 Ab Science Selective protein kinase inhibitors
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2016153023A1 (ja) 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
CN105030776A (zh) * 2015-06-24 2015-11-11 北京键凯科技有限公司 Src蛋白抑制剂在制备预防和/治疗阿尔兹海默病药物中的应用
CN106905298A (zh) * 2015-12-22 2017-06-30 江苏先声药业有限公司 盐酸尼洛替尼杂质的制备方法
WO2018148533A1 (en) 2017-02-09 2018-08-16 Georgetown University Compositions and methods for treating lysosomal storage disorders
US12290516B2 (en) * 2017-05-12 2025-05-06 The Hong Kong University Of Science And Technology Heterocyclic compounds as EphA4 inhibitors
US12559470B2 (en) 2018-09-13 2026-02-24 University Of Southern California FGFR inhibitors and uses thereof
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
US20220048893A1 (en) * 2019-03-05 2022-02-17 Hongyi & Associates Llc Compounds for Treating Neurodegenerative Diseases and Cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5728708A (en) 1993-10-01 1998-03-17 Novartis Corporation Pharmacologically active pyridine derivatives and processes for the preparation thereof
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP4827737B2 (ja) アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用
CN1960731B (zh) 调节炎性和转移过程的方法
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2009017455A1 (en) A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JP2011530607A5 (enExample)
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
JP2009542638A5 (enExample)
JP2007523181A5 (enExample)
HUP0202399A2 (hu) Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására
JP2009532438A5 (enExample)
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
AU2020229558A1 (en) Combinational medication
WO2018216705A1 (ja) 神経変性疾患の予防及び／又は治療剤
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
TWI565466B (zh) 由α－碳酸酐酶之異形體調節之哺乳動物之疾病之治療
JP2009537606A5 (enExample)
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
BRPI0710496A2 (pt) combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
JP5936821B2 (ja) チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
CN116829548A (zh) 作为c-abl抑制剂的吡唑衍生物
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合